Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Gynecology

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 35 articles:
HTML format
Text format



Single Articles


    May 2017
  1. CONDORELLI R, Andre F
    Combining PI3K and PARP inhibitors for breast and ovarian cancer tratement.
    Ann Oncol. 2017 May 15. doi: 10.1093.
    PubMed     Text format    


  2. BAMIAS A, Gibbs E, Khoon Lee C, Davies L, et al
    Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.
    Ann Oncol. 2017 May 8. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. LEONARD R, Adamson D, Bertelli G, Mansi J, et al
    GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial.
    Ann Oncol. 2017 May 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. MONK BJ, Brady MF, Aghajanian C, Lankes HA, et al
    A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
    Ann Oncol. 2017;28:996-1004.
    PubMed     Text format     Abstract available


    April 2017
  5. EYSBOUTS YK, Ottevanger PB, Massuger LFAG, IntHout J, et al
    Can the FIGO 2000 scoring system for gestational trophoblastic neoplasia (GTN) be simplified? A new retrospective analysis from a nationwide data-set.
    Ann Oncol. 2017 Apr 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  6. CHIANNILKULCHAI N, Pautier P, Genestie C, Bats AS, et al
    Networking for ovarian rare tumors: a significant breakthrough improving disease management.
    Ann Oncol. 2017 Apr 7. doi: 10.1093.
    PubMed     Text format     Abstract available


  7. RAY-COQUARD I, Lorusso D
    Immunotherapy and Epithelial Ovarian Cancer: a double-edged sword?
    Ann Oncol. 2017 Apr 3. doi: 10.1093.
    PubMed     Text format    


    March 2017
  8. POVEDA A, Del Campo JM, Ray-Coquard I, Alexandre J, et al
    Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.
    Ann Oncol. 2017 Mar 20. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  9. MONK BJ, Brady MF, Aghajanian C, Lankes HA, et al
    A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. KARAM A, Ledermann JA, Kim JW, Sehouli J, et al
    Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.
    Ann Oncol. 2017 Feb 21. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2017
  11. MCGEE J, Bookman M, Harter P, Marth C, et al
    5th Ovarian Cancer Consensus Conference: Individualized Therapy and Patient Factors.
    Ann Oncol. 2017 Jan 24. pii: mdx010. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. POWELL MA
    Immunohistochemistry to determine mismatch repair-deficiency in endometrial cancer: the appropriate standard.
    Ann Oncol. 2017;28:9-10.
    PubMed     Text format    


    December 2016
  13. KHOSROW-KHAVAR F, Filion KB, Al-Qurashi S, Torabi N, et al
    Cardiotoxicity of Aromatase Inhibitors and Tamoxifen in Post-Menopausal Women with Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Ann Oncol. 2016 Dec 20. pii: mdw673. doi: 10.1093.
    PubMed     Text format     Abstract available


  14. POWELL MA
    Immunohistochemistry to determine mismatch repair-deficiency in endometrial cancer: The appropriate standard.
    Ann Oncol. 2016.
    PubMed     Text format    


  15. WILSON MK, Pujade-Lauraine E, Aoki D, Mirza MR, et al
    5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recurrent Disease.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  16. MATULONIS UA, Wulf GM, Barry WT, Birrer M, et al
    Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer.
    Ann Oncol. 2016 Dec 19. pii: mdw672. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. LEARY AF, Quinn M, Fujiwara K, Coleman RL, et al
    5th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): Clinical trial design for rare ovarian tumours.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    November 2016
  18. MESNAGE SJ, Auguste A, Genestie C, Dunant A, et al
    Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  19. LIU JF, Moore KN, Birrer MJ, Berlin S, et al
    Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer.
    Ann Oncol. 2016;27:2124-2130.
    PubMed     Text format     Abstract available


  20. WEIDERPASS E, Botteri E
    Ovarian cancer mortality trends: which factors are involved?
    Ann Oncol. 2016;27:1977-1978.
    PubMed     Text format    


  21. MANGILI G, Sigismondi C, Lorusso D, Cormio G, et al
    The role of staging and adjuvant chemotherapy in stage I Malignant ovarian germ cell tumors (MOGTs): the MITO-9 study.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  22. STELLOO E, Jansen AM, Osse EM, Nout RA, et al
    Practical guidance for mismatch repair-deficiency testing in endometrial cancer.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  23. MALVEZZI M, Carioli G, Rodriguez T, Negri E, et al
    Global trends and predictions in ovarian cancer mortality.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  24. LEDERMANN JA, Sessa C, Colombo N
    appendix 7: Ovarian cancer: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Gynaecological-Malignancies).
    Ann Oncol. 2016;27.
    PubMed     Text format    


  25. PALUCH-SHIMON S, Cardoso F, Sessa C, Balmana J, et al
    Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening.
    Ann Oncol. 2016;27.
    PubMed     Text format    


    August 2016
  26. BENTIVEGNA E, Gouy S, Maulard A, Pautier P, et al
    FERTILITY-SPARING SURGERY IN EPITHELIAL OVARIAN CANCER: A SYSTEMATIC REVIEW OF ONCOLOGICAL ISSUES.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  27. CHO Y, Kim KH, Yoon HI, Kim GE, et al
    Tumor-related leukocytosis is associated with poor radiation response and clinical outcome in uterine cervical cancer patients.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  28. PAPATLA K, Huang M, Slomovitz B
    The obese endometrial cancer patient: how do we effectively improve morbidity and mortality in this patient population?
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  29. LINDEMANN K, Kristensen G, Mirza MR, Davies L, et al
    Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  30. RUSTIN GJ, Hall MR
    Is CA125 useful in monitoring patients with platinum resistant ovarian cancer?
    Ann Oncol. 2016.
    PubMed     Text format    


  31. MCNEISH IA
    Prognostic pathways in early stage ovarian cancer - can gene expression transcend histological subtype?
    Ann Oncol. 2016.
    PubMed     Text format    


  32. VOLGGER BM, Windbichler GH, Zeimet AG, Graf AH, et al
    LONG-TERM SIGNIFICANCE OF URINARY NEOPTERIN IN OVARIAN CANCER - A STUDY BY THE AUSTRIAN ASSOCIATION FOR GYNECOLOGIC ONCOLOGY (AGO).
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


  33. TRILLSCH F, Mahner S, Hilpert F, Davies L, et al
    Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    May 2016
  34. CALURA E, Paracchini L, Fruscio R, Di Feo A, et al
    A prognostic regulatory pathway in stage I Epithelial Ovarian Cancer: new hints for the poor prognosis assessment.
    Ann Oncol. 2016.
    PubMed     Text format     Abstract available


    December 2014
  35. SCHOFFSKI P, Besse B, Gauler T, de Jonge MJ, et al
    Efficacy and safety of biweekly intravenous administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small cell and non-small cell l
    Ann Oncol. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: